Review article · 2021 · Open access

Triple-negative breast cancer: understanding Wnt signaling in drug resistance

Parnaz Merikhian, Mohammad Reza Eisavand, Leila Farahmand

Cancer Cell International, 21(1), 419 · Published 10 August 2021 · DOI 10.1186/s12935-021-02107-3

Open PDFView at the publisherCite this paper

In brief

“Triple-negative breast cancer: understanding Wnt signaling in drug resistance” is a 2021 review article by Parnaz Merikhian and 2 co-authors, published in Cancer Cell International. OpenAlex counts 114 citations as of 21 November 2026, which puts it in the top 8% of works published in 2021 by citations. It is open access under a CC BY licence: the full text is free to read at Cancer Cell International.

Citations
114
Most cited in
2025 (34)
Field-weighted impact
1.68
References
58
Authors
3

Abstract

Triple-negative breast cancer (TNBC) is not as prevalent as hormone receptor or HER2-positive breast cancers and all receptor tests come back negative. More importantly, the heterogeneity and complexity of the TNBC on the molecular and clinical levels have limited the successful development of novel therapeutic strategies and led to intrinsic or developed resistance to chemotherapies and new therapeutic agents. Studies have demonstrated deregulation of Wnt/β-catenin signaling in tumorigenesis which plays decisive roles at the low survival rate of patients and facilitates resistance to currently existing therapies. This review summarizes mechanisms of Wnt/β-catenin signaling for resistance development in TNBC, the complex interaction between Wnt/β-catenin signaling, and the transactivated receptor tyrosine kinase (RTK) signaling pathways, lymphocytic infiltration, epithelial-mesenchymal transition (EMT), and induction of metastasis. Such associations and how these pathways interact in the development and progression of cancer have led to the careful analysis and development of new and effective combination therapies without generating significant toxicity and resistance.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Merikhian, P., Eisavand, M. R., & Farahmand, L. (2021). Triple-negative breast cancer: understanding Wnt signaling in drug resistance. Cancer Cell International, 21(1), 419. https://doi.org/10.1186/s12935-021-02107-3

MLA 9

Merikhian, Parnaz, et al. “Triple-negative breast cancer: understanding Wnt signaling in drug resistance.” Cancer Cell International, vol. 21, no. 1, 2021, p. 419. https://doi.org/10.1186/s12935-021-02107-3.

Chicago

Merikhian, Parnaz, Mohammad Reza Eisavand, and Leila Farahmand. 2021. “Triple-negative breast cancer: understanding Wnt signaling in drug resistance.” Cancer Cell International 21 (1): 419. https://doi.org/10.1186/s12935-021-02107-3.

Harvard

Merikhian, P., Eisavand, M. R. and Farahmand, L. (2021) ‘Triple-negative breast cancer: understanding Wnt signaling in drug resistance’, Cancer Cell International, 21(1), p. 419. doi:10.1186/s12935-021-02107-3.

IEEE

P. Merikhian, M. R. Eisavand, and L. Farahmand, “Triple-negative breast cancer: understanding Wnt signaling in drug resistance,” Cancer Cell International, vol. 21, no. 1, p. 419, 2021, doi: 10.1186/s12935-021-02107-3.

BibTeX

@article{merikhian2021triple,
  title     = {{Triple-negative breast cancer: understanding Wnt signaling in drug resistance}},
  author    = {Merikhian, Parnaz and Eisavand, Mohammad Reza and Farahmand, Leila},
  journal   = {Cancer Cell International},
  year      = {2021},
  volume    = {21},
  number    = {1},
  pages     = {419},
  doi       = {10.1186/s12935-021-02107-3},
  url       = {https://doi.org/10.1186/s12935-021-02107-3}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202122
20221717
20231919
20243030
20253434
20261212

Its field-weighted citation impact is 1.68: it has been cited 1.68 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer

  • triple-negative breast cancer
  • Wnt/β-catenin signaling
  • drug resistance
  • chemoresistance
  • receptor tyrosine kinase signaling
  • lymphocyte infiltration
  • epithelial-mesenchymal transition
  • metastasis

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Merikhian, P., Eisavand, M. R., & Farahmand, L. (2021). Triple-negative breast cancer: understanding Wnt signaling in drug resistance. Cancer Cell International, 21(1), 419. https://doi.org/10.1186/s12935-021-02107-3

How many times has this paper been cited?

114 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Cancer Cell International: sign in and open the PDF from this page.

Who wrote this paper?

Parnaz Merikhian, Mohammad Reza Eisavand, Leila Farahmand.

What is the DOI of this paper?

10.1186/s12935-021-02107-3, permanently at https://doi.org/10.1186/s12935-021-02107-3. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.